Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11143901 | PMC |
| http://dx.doi.org/10.1016/j.jaccas.2024.102353 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The UnconTrust Database for Studies of Unconscious Semantic Processing and Attentional Allocation.
Sci Data
January 2025
School of Psychological Sciences, Tel Aviv University, Tel Aviv, Israel.
The question of what processes can take place without conscious awareness has generated extensive research. Yet there is still no consensus regarding the extent and scope of unconscious processing, and past research abounds with conflicting results. A possible reason for this lack of consensus is the diversity of methods in the field, as the methodological choices might influence the results.
View Article and Find Full Text PDFSynergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer.
Invest New Drugs
January 2025
School of Life Sciences, Jilin University, Changchun, China.
Due to the emergence of drug resistance, androgen receptor (AR)-targeted drugs still pose great challenges in the treatment of prostate cancer, and it is urgent to explore an innovative therapeutic strategy. MK-1775, a highly selective WEE1 inhibitor, is shown to have favorable therapeutic benefits in several solid tumor models. Recent evidence suggests that the combination of MK-1775 with DNA-damaging agents could lead to enhanced antitumor efficacy.
View Article and Find Full Text PDFPatient and public involvement and engagement to improve impact on antimicrobial resistance.
Nat Commun
January 2025
Fleming Initiative, Institute for Global Health Innovation, Imperial College London, South Kensington Campus, London, UK.
A step change is required in citizen awareness of the global antimicrobial resistance (AMR) health crisis. But we must move beyond awareness-raising to action, directly engaging and involving patients and public in scoping, testing and scaling solutions to ensure their adoption and impact.
View Article and Find Full Text PDFPredictors of response to low-dose amitriptyline for irritable bowel syndrome and efficacy and tolerability according to subtype: post hoc analyses from the ATLANTIS trial.
Gut
January 2025
Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK
Background: Low-dose amitriptyline, a tricyclic antidepressant (TCA), was superior to placebo for irritable bowel syndrome (IBS) in the AmitripTyline at Low-dose ANd Titrated for Irritable bowel syndrome as Second-line treatment (ATLANTIS) trial.
Objective: To perform post hoc analyses of ATLANTIS for predictors of response to, and tolerability of, a TCA.
Design: ATLANTIS randomised 463 adults with IBS to amitriptyline (232) or placebo (231).
AdipoRon's Impact on Alzheimer's Disease-A Systematic Review and Meta-Analysis.
Int J Mol Sci
January 2025
Autonomic Nervous System Center, School of Philosophy and Sciences, São Paulo State University, Marília 17525-902, São Paulo, Brazil.
Alzheimer's disease (AD) remains a leading cause of cognitive decline and mortality worldwide, characterized by neurodegeneration, synaptic deficiencies, and neuroinflammation. Despite advancements in early detection, diagnosis, and treatment, AD presents substantial challenges due to its complex pathology, heterogeneity, and the limited efficacy of current therapies. Consequently, there is a pressing need for novel therapeutic agents to target the multifaceted aspects of AD pathology, enhance current treatments, and minimize adverse effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!